Contact Admission

Email Us:

Call Us:

+84 0981 559 255

Send your documents:

09 Nguyen Gia Thieu Street, Dien Ngoc Ward, Dien Ban Town, Quang Nam Province, Vietnam

Best View

* The virus is not a living organism *

Development history of world medicine

Symbol of medicine

Need to Distinguish X-RAYS, CT SCAN, MRI, PET S. - Diagnostic imaging methods

RECRUITMENT: Clerical clerk

U.S. Approves Targeted Lung Cancer Therapy Datroway

The U.S. Food and Drug Administration (FDA) officially approved Datroway, marking a major breakthrough in the treatment of non-small cell lung cancer. What sets Datroway apart is that it belongs to the class of antibody-drug conjugates, a type of therapy often likened to a “guided missile” for its ability to precisely target cancer cells while leaving healthy ones unharmed.

How does Datroway work — and who stands to benefit?

A superior mechanism of action: Unlike traditional chemotherapy, Datroway targets the TROP protein found on the surface of tumor cells — a protein that appears in many types of cancer. This targeted approach allows for more precise attacks on cancer cells, significantly reducing side effects compared to systemic treatments.

Eligible patients:

This is the first approved therapy in the U.S. for non-small cell lung cancer (NSCLC) patients who have already undergone other treatments without success. More specifically, Datroway offers a much-needed option for individuals with advanced-stage EGFR-mutant NSCLC who have become resistant to prior therapies, regardless of the original mutation.
Previously, Datroway had also been approved for the treatment of a specific type of breast cancer.

Illustration of a cancerous tumor growing in the patient's left lung. Image: Cure

Strategic Partnership Behind the Success

Datroway is the result of a close collaboration between two pharmaceutical giants: AstraZeneca and Daiichi Sankyo. The companies began working together years ago, with their first jointly developed product being Enhertu. In 2020, they signed a co-development and commercialization agreement for Datroway worth up to $6 billion. Following the drug’s approval in the U.S., AstraZeneca paid Daiichi Sankyo $45 million as a key milestone in the partnership.

The Significance of This Breakthrough

Lung cancer remains one of the most common and deadliest cancers worldwide. According to the World Health Organization (WHO), there are approximately 2.2 million new cases and nearly 1.8 million deaths from lung cancer each year. Non-small cell lung cancer (NSCLC) accounts for about 85% of all cases. The approval of Datroway, which targets the TROP2 protein, represents a promising new approach for patients who have developed resistance to prior therapies — offering renewed hope for millions of people around the world.

Source: VnExpress